Moderna, which has seen its stock surge 250% over the past year as it helps vaccinate the world from the coronavirus, will officially enter the S&P 500 on July 21.
The news sent shares popping more than 8% to $282 in Friday’s session as the stock will likely be purchased by fund managers who benchmark to the S&P 500. But Jefferies analyst Michael Yee tells Yahoo Finance Live he thinks the run in Moderna stock (MRNA) is far from done.
“Moderna is the Tesla of biotech,” says Yee, pointing to…
Source link
